(Last updated : 2024-11-14 14:29:27)
  Hashimoto Yasunobu
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine  Department of Urology
   Position   Assistant Professor
■ Published papers
1. Original article  Prognostic impact of the administration of antibiotics and proton pump inhibitors in immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. 2024/07/03
2. Original article  Survival impact of glucocorticoid administration for adverse events during immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/07
3. Original article  Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up. 2024/05/07
4. Original article  Association between kidney function and outcomes following immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell carcinoma. 2024/04
5. Original article  First‑line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint
inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the efectiveness using real‑world data. 2024/04
Display all(75)
■ Academic conference presentation
1. Impact of corticosteroid administration on treatment effectiveness in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor-based combination therapy.  2024/05/03
2. Impact of gender on the efficacy of immune checkpoint inhibitor therapy in renal cell carcinoma.  2024/04/27
3. Antibiotic and proton pump inhibitor use and survival of patients receiving immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma.  2024/04/26
4. Clinical study of RAPN between RENAL Nephrometry Score 2-2-3-3 and 1-3-3-3.  2024/04/26
5. Impact of steroids for immune-related adverse events in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor combination therapy.  2024/04/26
Display all(100)
■ Education
1. 1994/04~1998/03 〔Doctoral course〕, Graduate School, Division of Medicine, Tokyo Women's Medical University, Completed,